Amyris’s Board of Directors appointed Han Kieftenbeld, currently Amyris CFO, as the Interim CEO. “John’s unwavering commitment and leadership have played a pivotal role in the development of Amyris’ Lab-to-Market technology platform and the establishment of our diverse portfolio of consumer brands. On behalf of the Board of Directors, I express my sincere appreciation to John for his substantial contributions throughout the past 16 years,” stated Geoffrey Duyk, Board Chair of Amyris.
Amyris also initiated a global reduction in headcount as a significant measure towards achieving its previously announced $250-million in cost reductions. Additional details were not disclosed.